TY - JOUR T1 - MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.121.262402 SP - jnumed.121.262402 AU - Anca M. Avram AU - Katherine Zukotynski AU - Helen Ruth Nadel AU - Luca M Giovanella Y1 - 2021/08/01 UR - http://jnm.snmjournals.org/content/early/2021/08/19/jnumed.121.262402.abstract N2 - In the past decade the management of differentiated thyroid cancer (DTC) underwent a paradigm shift towards the use of risk-stratification with the goal of maximizing benefit and minimizing morbidity of radioiodine (131I) therapy. 131I therapy is guided by information derived from surgical histopathology, molecular markers, postoperative diagnostic radioiodine scintigraphy and thyroglobulin (Tg) levels. 131I is used for diagnostic imaging and therapy of DTC based on physiologic sodium-iodine symporter expression in normal and neoplastic thyroid tissue. We summarize the essential information at the core of multidisciplinary DTC management, which emphasizes individualization of 131I therapy according to the patient’s risk for tumor recurrence. ER -